CD19与CD22双靶向嵌合抗原受体T细胞联合治疗儿童B细胞急性淋巴细胞白血病:单臂多中心II期试验
该II期试验纳入225例年龄≤20岁的难治性或高危血液学或孤立性髓外复发B细胞急性淋巴细胞白血病患者,评估CD19与CD22 CAR-T细胞联合输注的安全性和疗效。结果显示,194例难治性或血液学复发患者完全缓解率达99.0%,12个月无事件生存率为73.5%;细胞因子释放综合征发生率为88.0%,CAR-T细胞神经毒性发生率为20.9%,导致3例死亡。
要点
- 194例难治性或血液学复发患者完全缓解率为99.0%,均微小残留病灶阴性。
- 12个月无事件生存率:移植组85.0% vs 未移植组69.2%(P=0.03)。
- 6个月持续性B细胞缺乏的25例患者在12个月时均保持缓解。
核心结论
- CD19与CD22 CAR-T细胞联合治疗在儿童复发或难治性B细胞急性淋巴细胞白血病中达到相对持久的缓解,包括孤立性或合并髓外复发患者。
研究设计与样本
- 单臂、多中心、II期试验,于2019年9月17日至2021年12月31日纳入225例可评估的年龄≤20岁患者。
- 先进行安全性导入阶段以确定推荐剂量;对前30例接受治疗患者(其中27例接受推荐剂量)进行中期分析显示治疗安全有效后,按研究设计纳入额外患者。
主要发现
- 194例难治性白血病或血液学复发患者中,完全缓解率为99.0%,全部微小残留病灶阴性。
- 12个月无事件生存率为73.5%(95%CI 67.3-80.3)。
- 43例患者复发(24例CD19+/CD22+复发,16例CD19-/CD22+,1例CD19-/CD22-,2例未知)。
- 12个月无事件生存率:接受移植的78例患者为85.0%(95%CI 77.2-93.6),未移植的116例患者为69.2%(95%CI 60.8-78.8)(P=0.03,时间依赖协变量Cox模型)。
- 6个月时持续性B细胞缺乏的25例患者在12个月时均保持缓解;20例孤立性睾丸复发患者12个月无事件生存率为95.0%(95%CI 85.9-100),10例孤立性中枢神经系统复发患者为68.6%(95%CI 44.5-100)。
关键数值与推荐
- 细胞因子释放综合征发生于198例(88.0%)患者,CAR-T细胞神经毒性发生于47例(20.9%)患者,导致3例死亡。
临床怎么用
- 巩固性移植和6个月时持续性B细胞缺乏与有利结局相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We determined the safety and efficacy of coadministration of CD19- and CD22-chimeric antigen receptor (CAR) T cells in patients with refractory disease or high-risk hematologic or isolated extramedullary relapse of B-acute lymphoblastic leukemia. PATIENTS AND METHODS: This phase II trial enrolled 225 evaluable patients age ≤ 20 years between September 17, 2019, and December 31, 2021. We first conducted a safety run-in stage to determine the recommended dose. After interim analysis of the first 30 patients treated (27 at the recommended dose) showing that the treatment was safe and effective, the study enrolled additional patients according to the study design. RESULTS: Complete remission was achieved in 99.0% of the 194 patients with refractory leukemia or hematologic relapse, all negative for minimal residual disease. Their overall 12-month event-free survival (EFS) was 73.5% (95% CI, 67.3 to 80.3). Relapse occurred in 43 patients (24 with CD19+/CD22+ relapse, 16 CD19-/CD22+, one CD19-/CD22-, and two unknown). Consolidative transplantation and persistent B-cell aplasia at 6 months were associated with favorable outcomes. The 12-month EFS was 85.0% (95% CI, 77.2 to 93.6) for the 78 patients treated with transplantation and 69.2% (95% CI, 60.8 to 78.8) for the 116 nontransplanted patients (P = .03, time-dependent covariate Cox model). All 25 patients with persistent B-cell aplasia at 6 months remained in remission at 12 months. The 12-month EFS for the 20 patients with isolated testicular relapse was 95.0% (95% CI, 85.9 to 100), and for the 10 patients with isolated CNS relapse, it was 68.6% (95% CI, 44.5 to 100). Cytokine release syndrome developed in 198 (88.0%) patients, and CAR T-cell neurotoxicity in 47 (20.9%), resulting in three deaths. CONCLUSION: CD19-/CD22-CAR T-cell therapy achieved relatively durable remission in children with relapsed or refractory B-acute lymphoblastic leukemia, including those with isolated or combined extramedullary relapse. UNLABELLED: [Media: see text].
引用
- Wang T, Tang Y, Cai J, et al. Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial. J Clin Oncol. 2022. PMID: 36346962. doi:10.1200/JCO.22.01214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。